MENU
XBI
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

XBI stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
XBI
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for XBI with price predictions
Oct 09, 2026

XBI in downward trend: price dove below 50-day moving average on September 23, 2026

XBI moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 45 of 50 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The 10-day moving average for XBI crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for XBI entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 60 cases where XBI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

Following a +0.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 297 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the State Street SPDR S&P Biotech ETF (XBI) ETF is 14.52B. The market cap for tickers in the group ranges from 199.9M to 470.55B. ABBV holds the highest valuation in this group at 470.55B. The lowest valued company is CMPX at 199.9M.

High and low price notable news

The average weekly price growth across all stocks in the State Street SPDR S&P Biotech ETF (XBI) ETF was -0%. For the same ETF, the average monthly price growth was -4%, and the average quarterly price growth was 19%. PRME experienced the highest price growth at 34%, while AVBP experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the State Street SPDR S&P Biotech ETF (XBI) ETF was 3%. For the same stocks of the ETF, the average monthly volume growth was 20% and the average quarterly volume growth was -25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 70
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 81
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
XBI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com
XBI in downward trend: price dove below 50-day moving average on September 23, 2026